Cargando…

Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies

Molecular tests that detect and/or quantify HCV RNA are important in the diagnosis and management of patients with chronic hepatitis C (CHC) undergoing anti-viral therapy. The primary goal of anti-HCV therapy is to achieve a sustained virologic response (SVR) defined as "undetectable" Hepa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cobb, Bryan, Heilek, Gabrielle, Vilchez, Regis A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160902/
https://www.ncbi.nlm.nih.gov/pubmed/25236936
http://dx.doi.org/10.1186/1471-2334-14-S5-S8
_version_ 1782334463027445760
author Cobb, Bryan
Heilek, Gabrielle
Vilchez, Regis A
author_facet Cobb, Bryan
Heilek, Gabrielle
Vilchez, Regis A
author_sort Cobb, Bryan
collection PubMed
description Molecular tests that detect and/or quantify HCV RNA are important in the diagnosis and management of patients with chronic hepatitis C (CHC) undergoing anti-viral therapy. The primary goal of anti-HCV therapy is to achieve a sustained virologic response (SVR) defined as "undetectable" Hepatitis C Virus (HCV) RNA in the serum or plasma at 12 to 24 weeks following the end of treatment. HCV RNA viral load (VL) monitoring is used to guide treatment duration where decisions can be made on-therapy and to determine whether or not to stop therapy. In addition, clinicians determine treatment regimen and duration based on the HCV genotype (1-6) as well as the kinetics of HCV RNA levels. As direct acting antivirals (DAA) have revolutionized hepatitis C treatment, they have also lead to new HCV RNA VL result interpretations. Further, the clinical decisions were different for pegylated-interferon/ribavirin (PEGα/RBV)+ boceprevir or telaprevir-containing regimens approved in 2011 (e.g. one requiring an additional 4 week "lead-in" with PEGα/RBV), each having different HCV RNA values for futility rules, created complexity in clinical decisions. The future pegylated-interferon free DAA- regimens promise significantly improved cure rates along with fixed durations and simpler treatment rules. The intent of this article is to discuss the role of HCV RNA real-time PCR tests used in the management of CHC patients in the past and how this is likely to change in the era of interferon free DAA regimens.
format Online
Article
Text
id pubmed-4160902
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41609022014-09-25 Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies Cobb, Bryan Heilek, Gabrielle Vilchez, Regis A BMC Infect Dis Review Molecular tests that detect and/or quantify HCV RNA are important in the diagnosis and management of patients with chronic hepatitis C (CHC) undergoing anti-viral therapy. The primary goal of anti-HCV therapy is to achieve a sustained virologic response (SVR) defined as "undetectable" Hepatitis C Virus (HCV) RNA in the serum or plasma at 12 to 24 weeks following the end of treatment. HCV RNA viral load (VL) monitoring is used to guide treatment duration where decisions can be made on-therapy and to determine whether or not to stop therapy. In addition, clinicians determine treatment regimen and duration based on the HCV genotype (1-6) as well as the kinetics of HCV RNA levels. As direct acting antivirals (DAA) have revolutionized hepatitis C treatment, they have also lead to new HCV RNA VL result interpretations. Further, the clinical decisions were different for pegylated-interferon/ribavirin (PEGα/RBV)+ boceprevir or telaprevir-containing regimens approved in 2011 (e.g. one requiring an additional 4 week "lead-in" with PEGα/RBV), each having different HCV RNA values for futility rules, created complexity in clinical decisions. The future pegylated-interferon free DAA- regimens promise significantly improved cure rates along with fixed durations and simpler treatment rules. The intent of this article is to discuss the role of HCV RNA real-time PCR tests used in the management of CHC patients in the past and how this is likely to change in the era of interferon free DAA regimens. BioMed Central 2014-09-05 /pmc/articles/PMC4160902/ /pubmed/25236936 http://dx.doi.org/10.1186/1471-2334-14-S5-S8 Text en Copyright © 2014 Cobb et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Cobb, Bryan
Heilek, Gabrielle
Vilchez, Regis A
Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies
title Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies
title_full Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies
title_fullStr Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies
title_full_unstemmed Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies
title_short Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies
title_sort molecular diagnostics in the management of chronic hepatitis c: key considerations in the era of new antiviral therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160902/
https://www.ncbi.nlm.nih.gov/pubmed/25236936
http://dx.doi.org/10.1186/1471-2334-14-S5-S8
work_keys_str_mv AT cobbbryan moleculardiagnosticsinthemanagementofchronichepatitisckeyconsiderationsintheeraofnewantiviraltherapies
AT heilekgabrielle moleculardiagnosticsinthemanagementofchronichepatitisckeyconsiderationsintheeraofnewantiviraltherapies
AT vilchezregisa moleculardiagnosticsinthemanagementofchronichepatitisckeyconsiderationsintheeraofnewantiviraltherapies